Veloxis Pharmaceuticals to Present Results from a Patient Subgroup Analysis of ... MarketWatch (press release) This subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrolimus and there is evidence to suggest a lower acute rejection rate. We are now looking forward to reviewing ... |
